Mitochondrial trifunctional protein deficiency

Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting

Retrieved on: 
Monday, August 29, 2022

The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.

Key Points: 
  • The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.
  • Improvements in 12-minute walk test distance and physical functioning scores were observed in a subgroup of patients.
  • The poster presentations elaborate on results first announced by the company in July 2022 and highlight the unmet medical need of patients with LC-FAOD.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.

Key Points: 
  • IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.
  • The second quarter was a very productive period for the company, highlighted by advancements in both of our mitochondrial disease programs, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • The Company had approximately $127 million in cash, cash equivalents and short-term investments as of June30, 2022.
  • Research and development expenses for the three months ended June30, 2022 were $8.1 million, compared to $6.3 million for the three months ended June30, 2021.